LON:OKYO OKYO Pharma (OKYO) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About OKYO Pharma Stock (LON:OKYO) 30 days 90 days 365 days Advanced Chart Ad Timothy SykesCountdown to the biggest trade of my 25 yr careerTim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Get OKYO Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range 1.40▼ 1.4052-Week Range N/AVolume364,142 shsAverage Volume431,999 shsMarket Capitalization£23.24 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewOKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.Read More… Countdown to the biggest trade of my 25 yr career (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Receive OKYO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OKYO Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address OKYO Stock News HeadlinesOKYO Pharma to Present at International Tear Film and Ocular Surface Society ConferenceOctober 30 at 4:51 PM | markets.businessinsider.comOkyo Pharma announces first patient dosed in Phase 2 trial of OK-101October 23, 2024 | markets.businessinsider.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Optimistic Buy Rating for OKYO Pharma Limited Driven by Promising Phase 2 Trial of OK-101 in Unmet Medical Need for Neuropathic Corneal PainOctober 16, 2024 | markets.businessinsider.comOKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal PainOctober 16, 2024 | finance.yahoo.comOKYO Pharma (NASDAQ:OKYO) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comOKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye DiseaseAugust 27, 2024 | finanznachrichten.deInvesco Global Equity Income Trust Plc - Transaction in Own SharesAugust 15, 2024 | uk.finance.yahoo.comSee More Headlines OKYO Stock Analysis - Frequently Asked Questions How do I buy shares of OKYO Pharma? Shares of OKYO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of OKYO Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), AutoZone (AZO), Intel (INTC), TJX Companies (TJX), Aurora Cannabis (ACB) and Allied Gaming & Entertainment (AGAE). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolLON:OKYO CUSIPN/A CIKN/A Webwww.okyopharma.com Phone44 20 7495 2379FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-6,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-397.13% Return on Assets-154.72% Debt Debt-to-Equity Ratio1.65 Current Ratio0.83 Quick Ratio2.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash Flow28.00 Book ValueGBX (1) per share Price / BookN/AMiscellaneous Outstanding Shares1,660,000,000Free FloatN/AMarket Cap£23.24 million OptionableNot Optionable Beta-0.06 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (LON:OKYO) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.